Cipla Limited received final U.S. FDA approval for its generic version of Advair Diskus. The approval covers all three strengths of the fluticasone propionate and salmeterol inhalation powder used to treat asthma and COPD.
The U.S. market for this product is valued at approximately $908 million, according to IQVIA data. This marks the first dry powder inhaler approved from Cipla's New York-based manufacturing network.
The company plans to launch the product in the U.S. during the second quarter of fiscal year 2027. Cipla's share price rose 1.83% following the announcement.